NASDAQ:BRTX Biorestorative Therapies (BRTX) Stock Price, News & Analysis $0.22 -0.02 (-8.09%) Closing price 04:00 PM EasternExtended Trading$0.23 +0.00 (+1.33%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biorestorative Therapies Stock (NASDAQ:BRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BRTX alerts:Sign Up Key Stats Today's Range$0.22▼$0.2550-Day Range$0.20▼$0.3352-Week Range$0.19▼$2.05Volume1.31 million shsAverage Volume6.98 million shsMarket Capitalization$5.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment. Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions. Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.AI Generated. May Contain Errors. Read More Biorestorative Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreBRTX MarketRank™: Biorestorative Therapies scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingBiorestorative Therapies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBiorestorative Therapies has received no research coverage in the past 90 days.Read more about Biorestorative Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biorestorative Therapies are expected to grow in the coming year, from ($0.66) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biorestorative Therapies is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biorestorative Therapies is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiorestorative Therapies has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biorestorative Therapies' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.67% of the float of Biorestorative Therapies has been sold short.Short Interest Ratio / Days to CoverBiorestorative Therapies has a short interest ratio ("days to cover") of 0.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biorestorative Therapies has recently decreased by 27.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiorestorative Therapies does not currently pay a dividend.Dividend GrowthBiorestorative Therapies does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Biorestorative Therapies this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for BRTX on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat Follows2 people have added Biorestorative Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biorestorative Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders13.60% of the stock of Biorestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of Biorestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biorestorative Therapies' insider trading history. Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biorestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BRTX Stock News HeadlinesBioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseMay 7 at 12:00 PM | globenewswire.comBioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical PlatformApril 30, 2026 | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 7 at 1:00 AM | Brownstone Research (Ad)BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its ...April 21, 2026 | markets.businessinsider.comBioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical PlatformApril 21, 2026 | globenewswire.comBioRestorative Therapies (BRTX) price target decreased by 15.79% to 8.16April 9, 2026 | msn.comBioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical PlatformApril 7, 2026 | globenewswire.comBioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseMarch 30, 2026 | globenewswire.comSee More Headlines BRTX Stock Analysis - Frequently Asked Questions How have BRTX shares performed this year? Biorestorative Therapies' stock was trading at $1.1750 at the beginning of 2026. Since then, BRTX stock has decreased by 80.9% and is now trading at $0.2250. How were Biorestorative Therapies' earnings last quarter? Biorestorative Therapies, Inc. (NASDAQ:BRTX) posted its quarterly earnings data on Thursday, March, 26th. The company reported ($0.37) EPS for the quarter, meeting analysts' consensus estimates of ($0.37). The firm earned $0.02 million during the quarter, compared to analyst estimates of $0.15 million. Biorestorative Therapies had a negative trailing twelve-month return on equity of 430.91% and a negative net margin of 3,956.11%. When did Biorestorative Therapies' stock split? Shares of Biorestorative Therapies reverse split before market open on Wednesday, October 27th 2021.The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. Is Biorestorative Therapies doing a stock buyback? Biorestorative Therapies' Board of Directors authorized a stock buyback program on Tuesday, June 17th 2025, which permits the company to repurchase $2,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 15.9% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued. How do I buy shares of Biorestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biorestorative Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biorestorative Therapies investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), American Graphite Technologies (AGIN). Company Calendar Last Earnings3/26/2026Today5/07/2026Next Earnings (Estimated)5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BRTX's financial health is in the Red zone, according to TradeSmith. BRTX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:BRTX Previous SymbolOTCMKTS:BRTX CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees7Year Founded1997Profitability EPS (Trailing Twelve Months)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.24 million Net Margins-3,956.11% Pretax Margin-3,956.11% Return on Equity-430.91% Return on Assets-203.61% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual Sales$360 thousand Price / Sales15.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book5.63Miscellaneous Outstanding Shares25,480,000Free Float22,013,000Market Cap$5.73 million OptionableNot Optionable Beta0.29 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BRTX) was last updated on 5/7/2026 by MarketBeat.com Staff. From Our PartnersIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biorestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biorestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
